INTERPACE BIOSCIENCES, INC. (IDXG): restructuring charge — Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage

INTERPACE BIOSCIENCES, INC.

Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.
Board approved restructuring plan Jan 14, 2025 due to CMS ending PancraGEN coverage (announced Jan 9, 2025).
Workforce reduction; severance costs estimated $0.8M–$1.0M, primarily recorded in Q1 2025.
Expected annual cost savings of $12.5M–$14.5M, expected to offset approximately one-third of revenue loss from PancraGEN.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

INTERPACE BIOSCIENCES, INC. announced a restructuring with charges of $0.8 million to $1.0 million affecting workforce related to PancraGEN® coverage loss (reducing its workforce).

Type: restructuring
Charge: $0.8 million to $1.0 million
Affected area: workforce related to PancraGEN® coverage loss
Headcount: reducing its workforce

Exact text from the filing

Plan, the Company is reducing its workforce and impacted employees will be eligible to receive severance benefits. The Company expects to incur severance costs in the range of $0.8 million to $1.0 million which will be recorded primarily in the first quarter of 2025. The substantial majority of the severance payments are expected to be made by the end of the second

View on SEC.gov

Browse all restructurings & charges →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-003019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.